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ABSTRACT
In vitro splicing of human A-globin pre-mRNA can be fully
inhibited by treatment of the splicing extract with polyclonal
antibodies against hnRNP core proteins prior to the addition
of pre-mRNA. Inhibition of the first step in the splicing
pathway, cleavage at the 5' splice site and lariat formation,
requires more antibodies than inhibition of the second step,
cleavage at the 3' splice site and exon ligation. The
anti-hnRNP antibodies can also inhibit the splicing reaction
after the formation of the active nucleoprotein splicing
complex which is known to occur during the initial lag period.
Thus, hnRNP core proteins appear to be present in the complex
that performs pre-mRNA splicing.
INTRODUCTION
In eukaryotes, pre-mRNA in the nucleus is found in
ribonucleoprotein particles (hnRNP, 1). These particles
contain a set of about 9 interrelated and evolutionarily
conserved major proteins, termed hnRNP core proteins (hr
32-42,000), and a number of minor protein components (2-4).
The core proteins form particles immediately after tran-
scription, but their specific function is unknown except for
their ability to protect the primary transcript from
degradation by ribonucleases (1). Since pre-mRNAs undergo a
series of RNA processing reactions in the nucleus, it seems
likely that these hnRNP particles, not the "naked" pre-mRNA,
serve as substrate for subsequent RNA processing steps. This
is also suggested by the requirement of a large 50S nucleo-
protein complex during in vitro splicing (5-7) and by the
recent observation that hnRNPs bind to splice junctions in
certain Drosophila transcripts (8). Since hnRNP core proteins
have a high affinity for RNA and will form particles with it
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in vitro (9-13), it seems plausible that these proteins
may be present in the splicing complex and involved in its
formation in the in vitro splicing reaction.
A useful vay of identifying the factors involved in RNA
processing is to inhibit one or more of the processing steps in
an in vitro reaction with antibodies directed against
particular nuclear components. This approach has been taken
using antibodies to small nuclear RNPs (snRNPs; Ul, U2, etc.)
and has shown convincingly that U1-RNP is a necessary splicing
factor (6,7, 14-16). In similar experiments, snRNPs have been
implicated in pre-mRNA polyadenylation (17). We report here
analogous observations using antibodies raised against
purified proteins isolated from hnRNP particles (18). These
antibodies are added to an in vitro splicing reaction with
truncated human 8-globin pre-mRNA transcripts as substrate.
Our results show that these antibodies can prevent the pre-mRNA
transcripts from undergoing any step in the splicing reaction.
In addition, under certain conditions, the antibodies can
inhibit the production of the final spliced product without
blocking the first step in the splicing reaction, i.e. cleavage
at the 5' splice site and lariat formation.
MATERIALS AND METHODS
DNA templates were prepared by linearizing the plasmid
pSP64HbA6 (19) with either restriction enzyme Bam HI or Acc I
which both cleave within the second exon of the human 8-globin
gene (Fig. lA). Transcription and capping of the substrate RNA
was carried out essentially as described by Konarska et al.
(20). In vitro splicing was carried out with nuclear extract
from HeLa cells (19,21) and the products analyzed on
polyacrylamide gels as previously described (22). Times of
incubation at 300 are indicated in the Figure Legends.
Anti-hnRNP serum was obtained by Lahiri and Thomas (18)
from chicken immunized with hnRNP proteins purified from bovine
brain nuclei. 40S hnRNP particles were obtained by extraction
of nuclei at pH 8, purified by sucrose density gradient
centrifugation, and further fractionated by ammonium sulfate
precipitation. This material was electrophoresed on a 12%
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SDS-polyacrylamide gel (23). Bands containing proteins with
molecular weight from 36-43 kDa were excised, emulsified with
Freund's adjuvants, and used to immunize chickens (18). IgG was
purified from chicken serum as described (24) and used in all
experiments reported here. Immunoblots were carried out
according to standard procedures (25). Biotinylated rabbit
anti-chicken secondary antibodies (Cooper Biomedical, Malvern,
PA) and avidin-biotin-horseradish peroxidase (Vectastain ABC
kit, Vector Labs, Burlingame, CA) were used for detection
according to manufacturers protocols. Immunoprecipitations of
[32P]-labeled HeLa cell sonicates were carried out as described
(26) using Pansorbin (Calbiochem, San Diego, CA) with an excess
of rabbit anti-chicken sera as secondary antibody (Cooper
Biomedical).
Inhibition of the processing reaction was carried out by
preincubating 24 pl of the reaction mixture (5mM ATP, 3.3mM
MgC12, 20mM creatine phosphate, 2.6% polyvinyl alcohol, 15 p1
nuclear extract) with an appropriate amount of the antibody
(see Fig. 3) for 30 minutes at 00. Subsequently, E32P]-labeled
RNA (105 cpm per sample) was added and the sample incubated for
90 minutes at 300. In experiments involving inhibition of a
splicing reaction already in progress (Fig. 4), a complete
reaction mixture including [32P]-labeled RNA was incubated for
30 minutes at 300 and then transferred on ice. One or 2 p1 of
the antibody was added, the incubation carried out for 30
minutes on ice, and then continued at 30°. The reaction
products were analyzed as above and further quantitated by
excision of appropriate RNA bands from polyacrylamide gels and
scintillation counting.
RESULTS
Structure and proDerties of the pre-mRNAs
Two truncated human 8-globin transcripts were tested in the
splicing assay (19,22). Transcript Bam HI (Fig. 1B) contains
the 5' exon, the small intron, and most of the second exon. It
is efficiently spliced in an in vitro system generating inter-
mediates and products that have been characterized in detail
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Figure 1. Structure of the DNA templates, pre-mRNA tran-
scripts, and intermediates and products of the splicing re-
action. A) The human B-globin DNA template (plasmid pSP64HBAS
(19). Restriction sites of Bam HI and Acc I which cleave
vithin the second exon of the gene are indicated. Open box
marked SP6, SP6 polymerase promoter; open boxes, exons; thin
line, intron; hatched area, transcribed sequences from the
cloning vector. Arrows represent RNA transcripts; their
length in nucleotides is indicated. B) Structure of
transcript Bam HI, terminating at Bam HI site, and the
intermediates and products of splicing. C) Structure of
transcript Acc I, terminating at Acc I site, and the products
of cleavage at the 5' splice site.
truncated within the second exon, 14 nucleotides downstream
from the 3' splice site, is efficiently cleaved at the 5'
splice site and forms a lariat at the correct branch point in
the intron but is unable to undergo cleavage at the 3' splice
site and exon ligation (22,28).
SpecificitY and puritY of the antibodies
The anti-hnRNP antibodies were raised in chicken against
gel purified core proteins isolated from hnRNP particles as
described in Materials and Methods (see also 18). The
molecular weight range of the core proteins is between 32-42
kDa which is in the range of some of the Sm- and U1-RNP
antigens (revieved in 29 and 30). In addition, snRNPs have
been shown to associate with hnRNPs (31). Thus it seemed
possible that hnRNP core proteins used for immunization might
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Fiaure 2. Immunoblot with anti-hnRNP antibodies. 75 pg of
crude nuclear extract or purified 40S hnRNPs from Hela cells
were separated on 12% SDS-polyacrylamide gel (23) and blotted
on nitrocellulose (25). The blot was reacted with anti-hnRNP
antibodies (1:100 dilution) and visualized as described in
Hethods. Lane 1 and 2, Coomasie brilliant blue stain of
nuclear extract and hnRNP, respectively. Lane 3 and 4,
immunoblot of nuclear extract and hnRNP, respectively.
have been contaminated with the Sm- or U1-RNP antigens, which
in turn would have led to the generation of anti-Sm or
anti-U1-RNP antibodies in the immune sera. Anti-Sm and
anti-Ul-RNP antibodies are known to inhibit splicing in a
similar assay (14-16) and their presence in the sera would have
invalidated the results described below. It was therefore
important to ascertain that the anti-hnRNP serum did not
exhibit any anti-Sm or anti-Ul-RNP specificity.
Several lines of evidence attest to the purity and specifi-
city of the antisera used in this report. As shown in Fig. 2,
immunoblots with anti-hnRNP antibodies of either crude nuclear
extracts (lane 3) or partially purified 40S hnRNP particles
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proteins (MW 32-42 KDa). No lower or higher protein bands
could be detected in this experiment, suggesting that common
Sm- or U1-RNP antigens (28 kDa, 16 kDa and 70 kDa) did not
react with the antibodies. Another possible contaminating
reactivity is for a 34 kDa U1-RNP protein (29,30). This
protein would not have been visible on the immunoblot since it
would have been obscured by the hnRNP proteins. To exclude the
possibility that anti-hnRNP serum contains antibodies against
this antigen, we have carried out immunoprecipitation of
[32P3-labeled sonicates from HeLa cells, using chicken
anti-hnRNP antibody, secondary rabbit anti-chicken antibody and
Pansorbin (protein A). Immunoprecipitation of U1-RNP or other
snRNPs could not be detected under these conditions (not
shown). Other tests for purity of the anti-hnRNP antibodies
such as immunoblots of purified Sm antigen (32) or immuno-
diffusion assay for anti-Sm or anti-Ul-RNP reactivity were also
negative (results not shown). Thus, we conclude that the
anti-hnRNP serum is devoid of any detectable anti-Sm or
anti-Ul-RNP activity and that the observed inhibition of
splicing, described below, is due to the anti-hnRNP specificity
of our sera.
Inhibition of splicing and cleavaae at the 5' splice site by
anti-hnRNP sera
Titration of the splicing extract (Fig. 3A and B, lanes
1-3) with anti-hnRNP core protein antibodies (18) prior to the
addition of the pre-mRNAs demonstrated that processing of both
transcripts (Bam HI and Acc I) can be completely inhibited
(Fig. 3A and B, lane 1) when 1 pl of antibody is used. At a
Ficure 3. Titration of the splicing extract with anti-hnRNP
core protein antibodies. A) Transcript Bam HI following
preincubation with: Lanes 1-3, anti-hnRNP core protein IgG
(60 mg protein/ml), 1.0, 0.3 and 0.1 pl, respectively; lane 4,
nonimmune chicken IgG (60 mg protein/ml), 1.0 pl; lane 5,
anti-hnRNP core protein IgG, 1.0 pl boiled for 10 minutes;
lane 6, bovine serum albumin (60 mg protein/ml), 1.0 pl; lane
7, gelatin (60 mg/ml), 1.0 pl. B) Transcript Acc I following
preincubation vith: Lanes 1-3, anti-hnRNP core protein IgG
1.0, 0.5, and 0.25 pl, respectively; lanes 4-7, as in panel A.
The 5' exon and the 3' part of transcript Acc I (band d)




lover level of anti-hnRNP antibodies (0.3 pl), the generation
of the spliced product from transcript Bar HI wam inhibited
(Fig. 3A, lane 2, absence of bands c and e) although cleavage
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Figure 4. Effect of anti-hnRNP core protein antibodies on
splicing after the lag period. A) Transcript Bam HI: Lane
1, input RNA; lanes 2 and 3, the complete reaction mixture
(see Methods and Fig. 3) was incubated at 300 for 15 and
30 minutes, respectively; lanes 4-6, the complete reaction
mixture was incubated for 30 minutes at 30°, kept on ice
for 30 minutes with 1.0 pl of antibodies per 25 pl aliquot
folloved by incubation at 300 for 15, 30 and 45 minutes,
respectively; lanes 7-9, as in lanes 4-6, except that the
incubation on ice was with nonimmune IgG, 1.0 pl per 25
pl aliquot. B) Transcript Acc I: Lanes 1-9, as in A,
except 2.0 pl of the anti-hnRNP antibodies and nonimmune
IgG per 25 pl aliquot were used in lanes 4-6 and 7-9,
respectively. C) Quantitation of the spliced product of
transcript Bam HI. Bands from lanes 4-9, Fig. 4A were
excised, their radioactivity determined, and the yields
calculated by dividing the amount of radioactivity in the
spliced product, band c, by the total amount of the
radioactivity in all RNA bands. Yield of spliced product
(time-course) with anti-hnRNP antibodies, 13--t3; with
nonimmune IgG, 0--0. D) Quantitation of products of
cleavage at the 5' splice site of transcript Acc I. Bands in
lanes 4-9, Fig. 4B were analyzed as above and the yield
calculated by dividing the amount of radioactivity in band d
by the sum found in bands a and d; anti-hnRNP antibodies,
U--U11; nonimmune IgG, S--S.
at the 5' splice site and lariat formation still occurred (same
lane, band b and d). Similarly, cleavage at the 5' splice site
of transcript Acc I was only partially inhibited by 0.5 pl of
the antibody and resistant to 0.25 pl (Fig. 3B, lanes 2 and 3,
respectively). This shows that the first step in the splicing
pathway, i.e. cleavage at the 5' splice site and lariat
formation, is less sensitive to inhibition by anti-hnRNP
antibodies than the subsequent step, cleavage at the 3' splice
5249




site and exon ligation (see also beloa, Fig. 4). Specificity
of inhibition by the antibodies is shown by the fact that
nonimmune and boiled immune IgG as well as albumin and gelatin
have no effect on the processing of both transcripts (Fig. 3A
and 3B, lanes 4-7).
We have attempted to preabsorb the anti-hnRNP antibody with
purified hnRNP particles or isolated core proteins to block
inhibition of splicing by the antibodies. These attempts were
unsuccessful, probably due to insufficient concentrations of
purified antigens. Higher amounts of proteins and hnRNPs
could not be used due to limitations of the volume that can be
added to the reaction without affecting the splicing activity.
Similar problems were encountered by Padgett et al. (14) in
experiments testing anti-Ul-RNP and anti-Sm sera in the
splicing assay.
Inhibition of solicina and cleavaae in the preformed snlicina
complex
In the experiments in Fig. 3, the nuclear extract was pre-
treated with the antibodies before the addition of the pre-
mRNAs. Under these conditions, antibodies presumably bind to
free core proteins or to hnRNP particles and prevent them from
participating in the formation of the active splicing complex
which occurs during the initial 30 minute lag period of the
splicing reaction (5-7, 19). To establish whether hnRNP core
proteins are present in the complex itself, the folloving
experiment was performed: The reaction mixture containing
transcript Bam HI was incubated for 30 minutes at 30°C to form
the splicing complex. The antibodies were added and the total
mixture was incubated on ice for 30 minutes to stop the
splicing reaction and allow the antibodies to react. After
that time, the reaction was continued at 300. A time course of
the splicing reaction folloving the addition of the antibodies
(Fig. 4A, lanes 4-6) or nonimmune IgG (Fig. 4A, lanes 7-9)
shows that anti-hnRNP antibodies inhibit splicing only
partially when the same amount is used (1 pl) which completely
inhibits splicing during pretreatment of the extract (see Fig.
3A, lane 1). Quantitative comparison of the yields of the
splicing reaction in the above experiment shows that splicing
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proceeds at a lover rate in the presence of anti-hnRNP
antibodies and is inhibited by about 50X (Fig. 4C). Doubling
the amount of the antibodies in this experiment results in
complete inhibition of splicing (not shown). In analogous
experiments with transcript Acc I, treatment of the samples
with an amount of anti-hnRNP antibodies that completely
inhibits 5' cleavage when added to the extract prior to the
addition of the transcript (1.0 pl, cf. Fig. 3B, lane 1) has no
inhibitory effect on the reaction (not shown). By adding 2 pl
of anti-hnRNP antibodies, cleavage at the 5' splice site is now
inhibited compared to nonimmune controls (Fig. 4B, lanes 4-6
vs 7-9, respectively). Quantitation of this experiment (shown
graphically in Fig. 4D) shows a drop in the rate of the 5'
cleavage reaction during the first 15 minutes after the
addition of the antibodies. At subsequent time points the
reaction was completely inhibited. Therefore, transcript Acc I
specifically shows that since higher amounts of antibodies are
required to inhibit the reaction after the lag period, the core
proteins are now less accessible to the antibodies.
It could be argued that anti-hnRNP antibodies may merely
prevent the fraction of the pre-mRNA which is not in the
splicing complex from entering it, without affecting the RNA
already in the complex. Were this the case, the RNA which is
in the complex after the lag period would be spliced regardless
of the concentration of the antibody in the reaction. Since 2
p1 of the antibody can completely inhibit splicing of
transcript Bam HI after the lag period, the antibodies are also
affecting the pre-mRNA already bound to the splicing factors in
the complex. Therefore, hnRNP proteins are involved in
splicing after the formation of the splicing complex.
DISCUSSION
In vivo, hnRNP particles form immediately after tran-
scription of pre-mRNA (1). The hnRNP core proteins consti-
tute the predominant protein component and provide the
structural framework of these particles (33). In vitro
nucleoprotein particles that resemble native hnRNP can be
reconstituted from core proteins and exogenous RNA (9-13). We
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show here that hnRNP core proteins are a necessary component of
splicing throughout the course of the reaction. The 5' splice
site cleavage and lariat formation reaction appears to be more
resistant to inhibition by anti-hnRNP antibodies than the
subsequent steps in splicing. This differential effect, as
well as the reduction in the degree of inhibition by the
antibody after the lag period, argues that inhibition is not
due to the removal of the transcript from the reaction mixture
by precipitation of a pre-mRNA hnRNP core protein complex, but
rather due to interference in splicing. Our results do not
suggest that hnRNPs are unnecessary for the early splicing
step. Instead, they imply that under conditions where the
antibodies are totally inhibiting the formation of the spliced
product, the components necessary for 5' cleavage are still
functional.
The elegant work of Choi et al. (34) demonstrates that
pretreatment of the splicing extract with monoclonal antibodies
to the C hnRNP proteins completely inhibits in vitro splicing
of an adenovirus-2 truncated transcript. It also shows by
means of immunodepletion experiment, that these proteins are
necessary for the formation of the splicing complex. Our
results obtained with a different splicing system and different
antibodies complement their work and confirm the involvement of
hnRNP proteins in the splicing phenomenon in general. Further-
more, we show in more detail that hnRNP proteins are needed for
both steps in pre-mRNA splicing.
The overall accumulated evidence suggests that all pre-mRNA
processing steps take place in a large multifunctional complex.
SnRNPs, in particular Ul (14,15), U2 (35) and possibly U5 (36),
were shown to be involved in splicing and appear to be a compo-
nent of the splicing complex. Anti-Ul-RNP and anti-La sera
inhibit in vitro polyadenylation (17) suggesting involvement of
snRNPs in this processing step. Similarly, our results and
those of Choi et al. (34) suggest that hnRNPu function in
splicing and Moore et al. has obtained evidence that monoclonal
anti-hnRNP antibodies inhibit polyadenylation in vitro (C.
Moore, MIT, personal communication). In addition, 5' cap
structures, and presumably cap binding protein. seem to be
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important for splicing (37), although not for polyadenylation
(17). The processing complex appears to be independent of
transcription since anti-Sm sera (14) and our anti-hnRNP
antibodies (unpublished results) do not inhibit pre-mRNA
transcription in vitro.
None of the data discussed above assigns a specific
function for hnRNPs or snRNPs in RNA processing. Since
purified hnRNP and snRNP particles are devoid of any known
enzymatic activity (33,38,39), it seems unlikely that they are
conducting any of the cleavage or ligation reactions
themselves. They are most probably either acting as a
foundation for the binding of the components that actually
catalyze the splicing reactions or, in the possible case of
self-splicing events (40), conforming the substrate into a
structural environment that allows these reactions to occur
under physiological conditions.
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